Kaposi's sarcoma (KS) is a malignant neoplasm of the vascular endothlium that closely related to human herpesvirus-8 (HHV-8) infection. Iatrogenic KS is associated with wide use of immunosuppressive therapy, which is well known in post-transplantation patient but only several cases reported in the literature associated with membranous glomerulonephritis. We herein report an unusual case of Kaposi's sarcoma in an HIV-negative patient with membranous glomerulonephritis from Sichuan, China. The 40-year-old male patient developed KS following treatment with long-term medium dose prednisolone, short-term cyclosporin and cyclophosphamide. The KS cases associated with glomerulonephritis are also reviewed.
INTRODUCTION
Kaposi's sarcoma is a low-grade vascular tumour of endothelial origin that most commonly involves the skin. The extent and aggressiveness of KS tumours depends on the epidemiology (classic, African, AIDS-associated and iatrogenic KS) and host immunity (1). Kaposi's sarcoma is well known in patients with acquired immunodeficiency syndrome (AIDS), iatrogenic KS mainly affecting recipients of solid organs (especially the kidneys), but rarely plaguing patients with glomerulonephritis under immunosuppressive therapy. To the best of our knowledge, the report of KS in patients with glomerulonephritis is only eight cases described in the literature (2) (3) (4) (5) (6) (7) (8) (9) . In this article, we are presenting another rare case of Kaposi sarcoma in a patient with membranous glomerulonephritis on immunosuppressive therapy.
CASE REPORT
A 40-year-old male patient presented with skin lesions that had appeared two months ago.
There was no history of any opportunistic infection before the onset of skin nodules.
His past medical history revealed that the patient was diagnosed with nephrotic syndrome one year earlier with a presentation of proteinuria. Clinical investigation at that time confirmed massive proteinuria (2.44 g/day), hypoalbuminaemia (28.1 g/L) and hyperlipidaemia.
The kidney function was within normal limits. Kidney biopsy was performed and showed atypical membranous glomerulonephritis. The patient was initially treated with prednisolone 65 mg/day orally (reduce 5 mg/month in the following four months). Then he had received additional immunosuppressive drugs during the last six months because of repeated colds and resistant proteinuria. First, six months ago, prednisolone 60 mg/day orally Haijiao et al 3 (reduce 5 mg/month in the following six months) was given again. Then four months ago, intravenous cyclophosphamide 0.5 g/day (two days in a row in a month, increase 0.5 g/day in the following two months) was given. At last, one month ago, cyclosporine 125 mg/day orally had been added to steroid for about one month's duration.
Clinical examination showed multiple, dusky red nodules and plaques over the feet, soles, thighs, fingers and hands (Figure 1 
Literature review
A Medline search (Pubmed and ovid) was performed to search for case reports published from 1966 to current. The keywords included Kaposi's sarcoma, glomerulonephritis. We finally identified eight cases without AIDS from the Medline search. Now there were a total of nine cases of coexistence of KS and glomerulonephritis without HIV infection including our case (Table 1 ). There are five men and four women, the age ranged from 30 to 78 years old.
There were four cases of MG, four of MPGN, one of FGS. Six patients (include two patients received an extra therapy of Mycophenolatemofetil) received a combination of corticosteroids and immunosuppressive drug therapy, which included cyclophosphamide, azathioprine, Tacrolimus and cyclosporine. Two patients received Prednisolone alone.
One patient developed Kaposi's sarcoma simultaneously without the initiation of prednisone.
The dose of corticosteroid ranging from 20 mg to 65 mg, the duration of drug therapy ranging from two months to seven years. The duration of KS presentation since diagnosed with glomerulonephritis ranging from one month to nine years. Kaposi's sarcoma lesions most involved extremities, other locations of involvement included eye, earlobe, axilla, face and tonsil, no inner organs were involved. Additionally, in some patients with KS, HHV-8 was not detected (Table 1) . These phenomena reminded us the development of iatrogenic KS may need other factors (like immune status, genetic, geographic and ethnic factors etc) other than immunosuppressive therapy and HHV-8.
Our patient received prednisolone, cyclophosphamide and cyclosporine because of glomerulonephritis, these immunosuppresive agents may deeply changed the immune status of patient, which provided opportunities for virus invasion or reactivation. The immune status may also directly leads to KS through some mechanisms.
In conclusion, as a rare complication of glomerulonephritis and other diseases under immunosuppressive therapy, KS is gradually drawing people's attention. Further studied and case report about patients with KS and glomerulonephritis are still needed.
Immunosuppression treatment should be carefully applied in clinical treatment and avoided if they are not essentially necessary.
